2,4-Dibromo-5-Thiazolecarboxaldehyde

When 5‑Formyl‑2,4‑dibromothiazole Enters the SDHI Pipeline

2,4‑Dibromo‑5‑thiazolecarboxaldehyde is charged into a 500‑L glass‑lined reactor equipped with a retreat‑curve impeller and nitrogen blanketing. The aldehyde stream is accepted for use only after a Karl Fischer titration confirms moisture content below 0.1% w/w (ASTM E1064‑21). A pre‑cooled solution of methylhydrazine in toluene is metered in at a rate that maintains the batch temperature between ‑5 °C and 0 °C; exotherm control is critical because runaway hydrazone formation above 8 °C accelerates oxidative by‑product generation that pushes the impurity profile beyond the 0.5% single‑unknown‑impurity limit required for registration‑support batches. After 1.5 h post‑addition stirring the hydrazone intermediate is telescoped without isolation into a reductive amination step using sodium cyanoborohydride at pH 4.5–5.0. The pH window is maintained by automated dosing of glacial acetic acid; excursions below pH 3.8 catalyze thiazole‑ring opening, while elevations above pH 5.5 stall imine reduction and leave residual aldehyde that co‑elutes with the desired hydrazine in downstream HPLC monitoring (USP <621>, C18 column, 254 nm detection).

Regioselective elaboration of the two bromine atoms dictates the architecture of the final succinate dehydrogenase inhibitor (SDHI) fungicide. The 4‑bromo substituent undergoes Suzuki–Miyaura coupling with 3‑(trifluoromethyl)phenylboronic acid first, using Pd(dppf)Cl₂ at 0.8 mol% loading and 2.0 eq of aqueous K₃PO₄ in a degassed 3:1 (v/v) dioxane/water mixture at 82 °C for 6 h. Process‑scale batches (200 kg input) routinely trigger an in‑line FTIR probe that monitors the disappearance of the 1698 cm⁻¹ carbonyl stretch; the endpoint is declared when the signal falls below the instrument’s 3:1 signal‑to‑noise threshold. After silica‑pad filtration and solvent switch to N,N‑dimethylacetamide, the 2‑bromo position is animated with 1.05 eq of 3‑aminopyridine under Buchwald–Hartwig conditions (Pd₂(dba)₃, Xantphos, Cs₂CO₃, 100 °C, 18 h). The crude product is crystallized twice from isopropanol/water to reach an assay of 98.7% and a palladium residue below 10 ppm (USP <232>). This sequence delivers the advanced pyrazole‑carboxamide building block that is converted to the commercial SDHI active ingredient after coupling with a difluoromethyl‑pyrazole‑carbonyl chloride unit. Plant‑scale production lines report that pre‑drying of toluene and dioxane to KF ≤ 50 ppm reduces debromination side products by a factor of 3–4. The final formulated fungicide is certified under CIPAC 4104 for suspension concentrate quality and must satisfy the 0‑h and 24‑h re‑emulsification criteria of FAO/WHO specification 2017.

Can Aldehyde‑Fulgide Condensation Outperform Conventional Dithienylethene Photochromes?

2,4‑Dibromo‑5‑thiazolecarboxaldehyde is condensed with diethyl succinate in a Stobbe‑type reaction to furnish a fulgide precursor that, after bromine‑directed functionalization, yields a thermally irreversible photochromic switch. The aldehyde and succinate are combined in anhydrous tert‑butanol containing 1.5 eq of potassium tert‑butoxide. The thick slurry is agitated in a planetary mixer until the exotherm levels off, then heated to 70 °C for 4 h to complete the half‑ester formation. On scale, the mixture usually passes through a gel phase at 40–50% conversion; maintaining the blade speed above 80 rpm prevents stagnation and localized overheating that generate the undesired γ‑keto ester. The isomeric half‑ester is then cyclized in acetic anhydride with 0.5 eq of sodium acetate at 90 °C. Distillation of acetic acid/acetic anhydride under 50 mbar vacuum leaves a dark oil; flash chromatography on deactivated silica (2% water pre‑adsorbed) delivers the core fulgide in 55–62% overall yield. The two bromine atoms are subsequently replaced by 4‑methoxyphenyl groups through Stille coupling with 2‑(tributylstannyl)anisole under Pd(PPh₃)₄ catalysis (1.0 mol%, toluene, 110 °C, 20 h). Careful exclusion of oxygen is mandatory during the Stille step because the stannane undergoes homocoupling in the presence of adventitious O₂, forming biaryl impurities that co‑precipitate.

Photochromic performance is evaluated on thin poly(methyl methacrylate) films doped with the dye at 0.5% w/w. Upon irradiation with a 365 nm LED array (15 mW cm⁻²), the colourless ring‑opened form converts to the violet‑blue closed‑ring isomer with a half‑life for thermal back‑reaction exceeding 6 months at 25 °C in the dark. The fatigue resistance under accelerated cycling (10 000 on‑off repeats) is monitored according to the optical density loss protocol described in ISO 8980‑3:2022 Annex B; thiazole‑derived fulgides generally retain ≥85% of the initial maximum absorbance when the switching is performed under argon‑saturated films, whereas aerobic cycling causes a 12–15% absorbance drop due to singlet‑oxygen‑mediated decomposition at the thiazole ring. Lens‑casting trials with polyurethane‑urea matrices (Shore D 82) confirm that the bromine‑to‑methoxyphenyl exchange shifts the absorption maximum from 512 nm to 548 nm, aligning with the photopic sensitivity curve demanded by ophthalmic product specifications. Commercialisation hinges on reducing residual tin below 5 ppm to satisfy EU Regulation 10/2011 for plastic food‑contact materials; a three‑stage carbon‑filtration polishing step is inserted before film casting for this purpose.

For the construction of bidentate (N,S) ligand systems used in late‑transition‑metal catalysis, 2,4‑dibromo‑5‑thiazolecarboxaldehyde is converted to a Schiff base by condensation with enantiopure primary amines bearing additional donor arms. The aldehyde and R‑(+)‑1‑(2‑pyridyl)ethylamine are refluxed in absolute ethanol with 1% v/v glacial acetic acid for 3 h. The yellow precipitate is filtered under a nitrogen blanket, washed with cold ethanol (‑20 °C), and dried at 40 °C/10 mbar to constant weight. The imine bond is sufficiently robust to tolerate subsequent lithiation‑halogen exchange at the 2‑position using n‑BuLi at ‑78 °C, followed by quenching with chlorodiphenylphosphine to install a ‑PPh₂ group. The 4‑bromo site remains intact because the electron‑withdrawing aldimine group deactivates the 4‑position toward metal‑halogen exchange under these kinetic conditions, a selectivity window confirmed by ³¹P{¹H} NMR monitoring. After aqueous work‑up and chromatography on basic alumina (Brockmann activity II), the mixed donor ligand is obtained as a pale‑yellow solid with a purity exceeding 97%. Its palladium(II) allyl chloride dimer complex generates TONs up to 12 000 in the asymmetric alkylation of 1,3‑diphenyl‑2‑propenyl acetate with dimethyl malonate, though published data for this specific configuration is limited to laboratory‑scale runs (<5 mmol substrate).

Thiazolo[5,4‑d]pyrimidine Scaffolds Accessed via Solvent‑Free Condensation

2,4‑Dibromo‑5‑thiazolecarboxaldehyde undergoes a solvent‑free, microwave‑promoted condensation with 6‑amino‑2‑thiouracil to build the thiazolo[5,4‑d]pyrimidine core found in several adenosine receptor antagonists. The aldehyde (1.0 eq) and the uracil (1.02 eq) are co‑ground in a planetary ball mill for 10 min to obtain an intimate powder mixture, which is then transferred to a heavy‑wall microwave vial equipped with a snap‑cap that allows pressure release above 20 bar. Irradiation at 130 °C for 25 min under a maximum power setting of 150 W produces a fused melt that solidifies upon cooling. The crude product is triturated with water, filtered, and dried to afford the tricyclic intermediate directly. The bromine atoms are then sequentially displaced: the 4‑position reacts with morpholine in ethanol at 60 °C within 1 h, while the 2‑position requires a higher temperature (120 °C) in a sealed tube with N‑methylpiperazine in butanol for 16 h. The differential reactivity arises from the electron‑withdrawing influence of the fused pyrimidine ring on the 4‑bromo substituent, confirmed by Hammett substituent constant calculations.

During process development, the principal obstacle is the generation of the des‑bromo analogue (thiazolo[5,4‑d]pyrimidin‑7‑one) when the aldehyde substrate contains trace acid—often carried over from insufficiently washed centrifuge cakes. Even 0.05% w/w of acetic acid catalysis triggers an alternative cyclocondensation pathway that yields the debrominated scaffold, which co‑crystallizes and cannot be removed by simple recrystallization. Manufacturers mitigate this by implementing a water‑wash pH ≥ 6.5 criterion for the incoming aldehyde lot and by adding 0.5 wt% of solid K₂CO₃ as an acid scavenger in the grinding step. The final active pharmaceutical ingredient intermediate is assayed against an in‑house reference standard cross‑validated under ICH Q2(R1) guidelines; mass balance of total impurities is kept below 0.3% (ICH Q3A). Any batch showing residual aldehydes above 0.10% is re‑slurried in 0.1 M sodium bisulfite solution to form the water‑soluble bisulfite adduct, which is removed by hot filtration, a procedure adapted from USP <1225> validation principles.

When Bromine Substituents Govern Stokes Shift in Cyanine Dyes

2,4‑Dibromo‑5‑thiazolecarboxaldehyde is condensed with a 1,3,3‑trimethyl‑2‑methyleneindoline derivative in acetic anhydride to generate a rigid merocyanine chromophore. The reaction is run under red‑light conditions (>600 nm cut‑off filter) because the product exhibits a high‑energy absorption tail that triggers photo‑isomerization and eventual cycloaddition. The aldehyde and the indolenine base are refluxed in a 1:1 (v/v) mixture of acetic anhydride and pyridine for 45 min; longer heating increases the proportion of the cis isomer that broadens the absorption envelope and reduces the extinction coefficient by 15–20%. The heavy‑atom effect of the two bromine atoms increases the first‑order rate constant of intersystem crossing to the triplet manifold, quantified by transient absorption spectroscopy at 532 nm probe wavelength. In aerated methanol, the singlet‑oxygen quantum yield of the dibromo‑thiazole cyanine reaches 0.55 ± 0.06 using 1,3‑diphenylisobenzofuran as a chemical scavenger (adapted from ISO 10705‑4:2001 principles).

The dye is sensitive to nucleophilic solvents; stock solutions are therefore prepared in dimethylformamide containing 0.1% v/v triethylamine to sequester trace protons that would otherwise protonate the thiazole nitrogen and shift the absorption maximum hypsochromically by 18–22 nm. Scale‑up has been performed in a 50‑L jacketed stainless‑steel reactor equipped with a high‑speed disperser; addition of the indolenine must occur at a linear tip speed below 3.5 m s⁻¹ to avoid shear‑induced aggregation of the forming dye. The precipitated crude is isolated by centrifugation, washed with cold acetone until the supernatant remains colourless, and dried under vacuum at 35 °C. Final purity suitable for photodynamic therapy research is confirmed by analytical HPLC (USP <621>) with a requirement of >97.0% area, and the residual palladium—trace catalyst sometimes used in precursor preparation—must not exceed 50 ppm to avoid dark cytotoxicity. The dye is shipped in amber glass vials under argon overpack, and a desiccant cartridge is inserted to maintain headspace relative humidity below 30%.